Latest newsClassic list
Globally incubate standards compliant channels before scalable benefits. Quickly disseminate superior deliverables whereas web-enabled applications.Latest newsNews
Credibly innovate granular internal or “organic“ sources whereas high standards in web-readiness. Energistically scale future-proof core competencies.
An open-source public database for all cough TB recordings which future researchers and the public can utilise and develop more tools that can address the TB burden through cough sounds.
CageTB has a focus in Automated smartphone-based cough audio classification for rapid tuberculosis triage testing (Cough Audio triaGE for TB) CAGE-TB.
Dr. Wayengera successfully developed a rapid diagnostic kit for Ebola. We are sure, under his leadership, Uganda had a response to COVID19 that is effective and efficient. He also came up with a Solution name: Pan-Filovirus Rapid Diagnostic Test Ebolavirus and Marburgvirus cause rare but fatal viral haemorrhagic fevers (VHFs) in remote villages of equatorial Africa. Both filovirus VHFs are highly infectious with potential for urban, regional and global spread. Early detection is important for VHFs epidemic prevention and control.
Whereas two rapid diagnostic tests (RDTs) have emerged on the scene for Zaire ebolavirus (EBOV), RDTs for other Ebolavirus species that cause VHFs in humans, such as Sudan ebolavirus-SUDV, Bundibugyo ebolavirus-BDBV, Tai Forest ebolavirus-TAFV and Marburgvirus-MARV are missing. Given the similarity of symptomatology among VHFs and other infectious diseases, it is clear that RDTs to combat filovirus VHFs are needed.
Prof. Moses Joloba was recognized by CDC Global for his effort to fight tuberculosis in Africa in the year 2022. Prof. Moses Joloba, Director of Uganda’s Nat’l. TB Reference Laboratory, has built capacity for #TB diagnosis & surveillance for 25+ years. His leadership was vital in the GeneXpert platform expansion, which helps diagnose drug resistant TB.
It is with great pleasure that I present to you the second Annual Report of the Makerere University Biomedical Research Centre (MakBRC), which captures our performance for the year 2021- 2022. The Centre is committed to demonstrating integrated thinking and value creation for our stakeholders, as well as sustainability for the future as we work towards championing biomedical sciences.
The MakBRC Board of Directors remains committed to providing an enabling corporate governance framework and supporting the company to achieve its five-year strategic plan.
I take this opportunity to reassure our stakeholders that the MakBRC is a center of sound repute, premised to build on its achievements. Our highly experienced leadership coupled with a competent team of staff members will always strive to deliver exceptional performance against the set targets.
On behalf of the Board of Directors, I thank all our stakeholders for supporting the organization. I equally thank the management and staff for innovatively transforming the company to what it is today.
Prof. William Buwembo
CHAIRMAN BOARD OF DIRECTORS
Nabukenya, S., Waitt, C., Senyonga, R., Castelnuovo, B., Munabi, I. G., Kyaddondo, D., & Mwaka, E. S. (2023). Research participants’ preferences for individual results of pharmacogenomics research: A Case of a Ugandan HIV Research Institute. Journal of Empirical Research on Human Research Ethics, 18(4), 218-232.
Mijumbi, A. O., Mugenyi, L., Nanfuka, M., Agaba, C., & Ochieng, J. (2023). Regulation of community advisory boards during conduct of clinical trials in Uganda: a qualitative study involving stakeholders. BMC Health Services Research, 23(1), 119.